10x Genomics, Inc. (NASDAQ:TXG) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET
Company Participants
Cassie Corneau - Director, Investor Relations and Strategic Finance
Serge Saxonov - CEO and Co-Founder
Justin McAnear - Chief Financial Officer
Conference Call Participants
Patrick Donnelly - Citi
Dan Arias - Stifel
Kyle Mikson - Canaccord Genuity
Dan Brennan - TD Cowen
Salem Salem - Barclays
Tejas Savant - Morgan Stanley
John Sourbeer - UBS
Mason Carrico - Stephens
Michael Ryskin - Bank of America
Justin Bowers - Deutsche Bank
Rachel Vatnsdal - JPMorgan
Operator
Thank you for standing by. My name is Aaron, and I will be your conference operator for today. At this time, I would like to welcome everyone to the 10x Genomics Third Quarter 2023 Earnings Conference Call. All lines have been placed in mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.
I would now like to turn our call over to Cassie Corneau, Director of Investor Relations and Strategic Finance. Please go ahead.
Cassie Corneau
Thank you and good afternoon, everyone. Earlier today, 10x Genomics released the financial results for the third quarter ended September 30th, 2023. If you have not received this news release or if you would like to be added to the company’s distribution list, please send an e-mail to investors at 10xgenomics.com. An archived webcast of this call will be available on the Investor tab of the company’s website, 10xgenomics.com for at least 45 days following this call.
Before we begin, I’d like to remind you that management will make statements during this call that are forward-looking statements within the meaning of Federal Securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated and you should not place undue reliance on forward-looking statements.
Additional information regarding these risks, uncertainties and factors that could cause results to differ appears in the press release 10x Genomics issued today, and in the documents and reports filed by 10x Genomics from time to time with the Securities and Exchange Commission. 10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements whether because of new information, future events or otherwise.
Joining the call today are Serge Saxonov, our CEO and Co-Founder; and Justin McAnear, our Chief Financial Officer. We will host the question-and-answer session after our prepared remarks. We ask analysts to please keep to one question and one follow-up so that we may accommodate everyone in the queue.